Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in Mice

Abstract

This study demonstrates that VLP vaccination provides effective protection against RSV infection. VLPs containing RSV-F and/or RSV-G are potential vaccine candidates against RSV.

Respiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T-cells partially through alveolar macrophages

“…[5][6][7][8][9] Compared to FI-RSV, immunization with RSV VLP vaccines induced a higher IgG2a/IgG1 antibody ratio, which refers to Th1 immune responses. 5,6 Nanoparticles of FG VLPs were shown to be in a range of 60-120 nm-size particles and produced in insect cells using the recombinant baculovirus expression system. 5 Alveolar macrophages (AMs) are the first defense line of innate immune cells in the respiratory tract.…”

“…5,6 Nanoparticles of FG VLPs were shown to be in a range of 60-120 nm-size particles and produced in insect cells using the recombinant baculovirus expression system. 5 Alveolar macrophages (AMs) are the first defense line of innate immune cells in the respiratory tract. AMs are a major resident cell in alveoli and interstitial spaces of the lung.…”

Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats

“…5 In the insect cell expression system, full length RSV F or G proteins were effectively incorporated into VLPs. 10 In cotton rats, this study demonstrated that F VLP was more immunogenic and effective in clearing lung viral titers than G VLP although both F VLP and G VLP did not cause weight loss and AHR lung disease after RSV challenge. FI-RSV immune and na€ ıve cotton rats showed high AHR representing RSV disease mimicking the RSV pathogenesis in humans.…”

“…Viral titers in individual lungs at day 5 after challenge were determined using an immune plaque assay as previous described. 10 Lung histopathology and flow cytometry…”

“…9 We have previously developed VLP vaccines containing RSV F (F VLP) or RSV G (G VLP) using influenza matrix M1 protein and the recombinant baculovirus / insect cell expression system. 10 F VLP was able to induce T helper type 1 (Th1) humoral and cellular immune responses conferring protection against RSV without vaccine-associated lung inflammation in mice. 11 In addition, a mixed F VLP and G VLP (FG VLP) was shown to have additive protection by reducing lung viral loads and inducing CD8 T cell responses in mice.…”